Fundraising Fox
GigaGen
South San Francisco, US · Delaware corporation
Find your way into GigaGen
Sign up to see every warm intro you have to GigaGen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GigaGen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
Founders & leadership
DJ
David JohnsonFounder and CEO2010–2021David Johnson is CEO of Waymark Clinical, which operates clinical trials using an AI platform; he previously founded GigaGen, developing recombinant antibody therapies that were sold to Grifols in 2021, and was among Natera's founding members and COO. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at UC Berkeley.
CW
Chuck WilsonNamed on SEC filing
CK
Carter KellerNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$36.1M disclosed across 1 round · 2017
▶$36.1MraisedJul 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$36.1MraisedJul 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chuck WilsonDirector
- Carter KellerDirector
- David JohnsonExecutive Officer, Director
- Offering amount
- $36.1M
- Amount sold
- $36.1M
- Proceeds to insiders
- $3M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
ExagenExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
Companies working in the same space as GigaGen.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $265K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $912.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $249.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $217.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.1M |
| National Science Foundation | Phase II | 2012 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $205.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $189.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $156.4K |
| Department of Energy | Phase I | 2012 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $201.6K |
| National Science Foundation | Phase I | 2011 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does GigaGen do?
- GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
- Who founded GigaGen?
- GigaGen was founded by David Johnson.
- How much funding has GigaGen raised?
- GigaGen has disclosed $36.1M raised across 1 round.
- Where is GigaGen headquartered?
- GigaGen is headquartered in South San Francisco, US.